Embolic protection and platelet inhibition during renal artery stenting

Christopher J. Cooper, Steven T. Haller, William Colyer, Michael W Steffes, Mark W. Burket, William J. Thomas, Robert Safian, Bhagat Reddy, Pamela Brewster, Mary Ann Ankenbrandt, Renu Virmani, Eric Dippel, Krishna Rocha-Singh, Timothy P. Murphy, David J. Kennedy, Joseph I. Shapiro, Ralph D. D'Agostino, Michael J. Pencina, Sadik Khuder

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

BACKGROUND - Preservation of renal function is an important objective of renal artery stent procedures. Although atheroembolization can cause renal dysfunction during renal stent procedures, whether adjunctive use of embolic protection devices or glycoprotein IIb/IIIa inhibitors improves renal function is unknown. METHODS AND RESULTS - One hundred patients undergoing renal artery stenting at 7 centers were randomly assigned to an open-label embolic protection device, Angioguard, or double-blind use of a platelet glycoprotein IIb/IIIa inhibitor, abciximab, in a 2×2 factorial design. The main effects of treatments and their interaction were assessed on percentage change in Modification in Diet in Renal Disease-derived glomerular filtration rate from baseline to 1 month using centrally analyzed creatinine. Filter devices were analyzed for the presence of platelet-rich thrombus. With stenting alone, stenting and embolic protection, and stenting with abciximab alone, glomerular filtration rate declined (P<0.05), but with combination therapy, it did not decline and was superior to the other allocations in the 2×2 design (P<0.01). The main effects of treatment demonstrated no overall improvement in glomerular filtration rate; although abciximab was superior to placebo (0±27% versus -10±20%; P<0.05), embolic protection was not (-1±28% versus -10±20%; P=0.08). An interaction was observed between abciximab and embolic protection (P<0.05), favoring combination treatment. Abciximab reduced the occurrence of platelet-rich emboli in the filters from 42% to 7% (P<0.01). CONCLUSIONS - Renal artery stenting alone, stenting with embolic protection, and stenting with abciximab were associated with a decline in glomerular filtration rate. An unanticipated interaction between Angioguard and abciximab was seen, with combination therapy better than no treatment or either treatment alone.

Original languageEnglish (US)
Pages (from-to)2752-2760
Number of pages9
JournalCirculation
Volume117
Issue number21
DOIs
StatePublished - May 1 2008

Fingerprint

Renal Artery
Blood Platelets
Glomerular Filtration Rate
Kidney
Embolic Protection Devices
Platelet Glycoprotein GPIIb-IIIa Complex
Therapeutics
Stents
Integrin beta3
Diet Therapy
abciximab
Embolism
Creatinine
Thrombosis
Placebos
Equipment and Supplies

Keywords

  • Kidney
  • Peripheral vascular disease
  • Platelets
  • Stenosis
  • Stents

Cite this

Cooper, C. J., Haller, S. T., Colyer, W., Steffes, M. W., Burket, M. W., Thomas, W. J., ... Khuder, S. (2008). Embolic protection and platelet inhibition during renal artery stenting. Circulation, 117(21), 2752-2760. https://doi.org/10.1161/CIRCULATIONAHA.107.730259

Embolic protection and platelet inhibition during renal artery stenting. / Cooper, Christopher J.; Haller, Steven T.; Colyer, William; Steffes, Michael W; Burket, Mark W.; Thomas, William J.; Safian, Robert; Reddy, Bhagat; Brewster, Pamela; Ankenbrandt, Mary Ann; Virmani, Renu; Dippel, Eric; Rocha-Singh, Krishna; Murphy, Timothy P.; Kennedy, David J.; Shapiro, Joseph I.; D'Agostino, Ralph D.; Pencina, Michael J.; Khuder, Sadik.

In: Circulation, Vol. 117, No. 21, 01.05.2008, p. 2752-2760.

Research output: Contribution to journalArticle

Cooper, CJ, Haller, ST, Colyer, W, Steffes, MW, Burket, MW, Thomas, WJ, Safian, R, Reddy, B, Brewster, P, Ankenbrandt, MA, Virmani, R, Dippel, E, Rocha-Singh, K, Murphy, TP, Kennedy, DJ, Shapiro, JI, D'Agostino, RD, Pencina, MJ & Khuder, S 2008, 'Embolic protection and platelet inhibition during renal artery stenting', Circulation, vol. 117, no. 21, pp. 2752-2760. https://doi.org/10.1161/CIRCULATIONAHA.107.730259
Cooper, Christopher J. ; Haller, Steven T. ; Colyer, William ; Steffes, Michael W ; Burket, Mark W. ; Thomas, William J. ; Safian, Robert ; Reddy, Bhagat ; Brewster, Pamela ; Ankenbrandt, Mary Ann ; Virmani, Renu ; Dippel, Eric ; Rocha-Singh, Krishna ; Murphy, Timothy P. ; Kennedy, David J. ; Shapiro, Joseph I. ; D'Agostino, Ralph D. ; Pencina, Michael J. ; Khuder, Sadik. / Embolic protection and platelet inhibition during renal artery stenting. In: Circulation. 2008 ; Vol. 117, No. 21. pp. 2752-2760.
@article{0e23fdf235564c1bbd6f26118af2a184,
title = "Embolic protection and platelet inhibition during renal artery stenting",
abstract = "BACKGROUND - Preservation of renal function is an important objective of renal artery stent procedures. Although atheroembolization can cause renal dysfunction during renal stent procedures, whether adjunctive use of embolic protection devices or glycoprotein IIb/IIIa inhibitors improves renal function is unknown. METHODS AND RESULTS - One hundred patients undergoing renal artery stenting at 7 centers were randomly assigned to an open-label embolic protection device, Angioguard, or double-blind use of a platelet glycoprotein IIb/IIIa inhibitor, abciximab, in a 2×2 factorial design. The main effects of treatments and their interaction were assessed on percentage change in Modification in Diet in Renal Disease-derived glomerular filtration rate from baseline to 1 month using centrally analyzed creatinine. Filter devices were analyzed for the presence of platelet-rich thrombus. With stenting alone, stenting and embolic protection, and stenting with abciximab alone, glomerular filtration rate declined (P<0.05), but with combination therapy, it did not decline and was superior to the other allocations in the 2×2 design (P<0.01). The main effects of treatment demonstrated no overall improvement in glomerular filtration rate; although abciximab was superior to placebo (0±27{\%} versus -10±20{\%}; P<0.05), embolic protection was not (-1±28{\%} versus -10±20{\%}; P=0.08). An interaction was observed between abciximab and embolic protection (P<0.05), favoring combination treatment. Abciximab reduced the occurrence of platelet-rich emboli in the filters from 42{\%} to 7{\%} (P<0.01). CONCLUSIONS - Renal artery stenting alone, stenting with embolic protection, and stenting with abciximab were associated with a decline in glomerular filtration rate. An unanticipated interaction between Angioguard and abciximab was seen, with combination therapy better than no treatment or either treatment alone.",
keywords = "Kidney, Peripheral vascular disease, Platelets, Stenosis, Stents",
author = "Cooper, {Christopher J.} and Haller, {Steven T.} and William Colyer and Steffes, {Michael W} and Burket, {Mark W.} and Thomas, {William J.} and Robert Safian and Bhagat Reddy and Pamela Brewster and Ankenbrandt, {Mary Ann} and Renu Virmani and Eric Dippel and Krishna Rocha-Singh and Murphy, {Timothy P.} and Kennedy, {David J.} and Shapiro, {Joseph I.} and D'Agostino, {Ralph D.} and Pencina, {Michael J.} and Sadik Khuder",
year = "2008",
month = "5",
day = "1",
doi = "10.1161/CIRCULATIONAHA.107.730259",
language = "English (US)",
volume = "117",
pages = "2752--2760",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "21",

}

TY - JOUR

T1 - Embolic protection and platelet inhibition during renal artery stenting

AU - Cooper, Christopher J.

AU - Haller, Steven T.

AU - Colyer, William

AU - Steffes, Michael W

AU - Burket, Mark W.

AU - Thomas, William J.

AU - Safian, Robert

AU - Reddy, Bhagat

AU - Brewster, Pamela

AU - Ankenbrandt, Mary Ann

AU - Virmani, Renu

AU - Dippel, Eric

AU - Rocha-Singh, Krishna

AU - Murphy, Timothy P.

AU - Kennedy, David J.

AU - Shapiro, Joseph I.

AU - D'Agostino, Ralph D.

AU - Pencina, Michael J.

AU - Khuder, Sadik

PY - 2008/5/1

Y1 - 2008/5/1

N2 - BACKGROUND - Preservation of renal function is an important objective of renal artery stent procedures. Although atheroembolization can cause renal dysfunction during renal stent procedures, whether adjunctive use of embolic protection devices or glycoprotein IIb/IIIa inhibitors improves renal function is unknown. METHODS AND RESULTS - One hundred patients undergoing renal artery stenting at 7 centers were randomly assigned to an open-label embolic protection device, Angioguard, or double-blind use of a platelet glycoprotein IIb/IIIa inhibitor, abciximab, in a 2×2 factorial design. The main effects of treatments and their interaction were assessed on percentage change in Modification in Diet in Renal Disease-derived glomerular filtration rate from baseline to 1 month using centrally analyzed creatinine. Filter devices were analyzed for the presence of platelet-rich thrombus. With stenting alone, stenting and embolic protection, and stenting with abciximab alone, glomerular filtration rate declined (P<0.05), but with combination therapy, it did not decline and was superior to the other allocations in the 2×2 design (P<0.01). The main effects of treatment demonstrated no overall improvement in glomerular filtration rate; although abciximab was superior to placebo (0±27% versus -10±20%; P<0.05), embolic protection was not (-1±28% versus -10±20%; P=0.08). An interaction was observed between abciximab and embolic protection (P<0.05), favoring combination treatment. Abciximab reduced the occurrence of platelet-rich emboli in the filters from 42% to 7% (P<0.01). CONCLUSIONS - Renal artery stenting alone, stenting with embolic protection, and stenting with abciximab were associated with a decline in glomerular filtration rate. An unanticipated interaction between Angioguard and abciximab was seen, with combination therapy better than no treatment or either treatment alone.

AB - BACKGROUND - Preservation of renal function is an important objective of renal artery stent procedures. Although atheroembolization can cause renal dysfunction during renal stent procedures, whether adjunctive use of embolic protection devices or glycoprotein IIb/IIIa inhibitors improves renal function is unknown. METHODS AND RESULTS - One hundred patients undergoing renal artery stenting at 7 centers were randomly assigned to an open-label embolic protection device, Angioguard, or double-blind use of a platelet glycoprotein IIb/IIIa inhibitor, abciximab, in a 2×2 factorial design. The main effects of treatments and their interaction were assessed on percentage change in Modification in Diet in Renal Disease-derived glomerular filtration rate from baseline to 1 month using centrally analyzed creatinine. Filter devices were analyzed for the presence of platelet-rich thrombus. With stenting alone, stenting and embolic protection, and stenting with abciximab alone, glomerular filtration rate declined (P<0.05), but with combination therapy, it did not decline and was superior to the other allocations in the 2×2 design (P<0.01). The main effects of treatment demonstrated no overall improvement in glomerular filtration rate; although abciximab was superior to placebo (0±27% versus -10±20%; P<0.05), embolic protection was not (-1±28% versus -10±20%; P=0.08). An interaction was observed between abciximab and embolic protection (P<0.05), favoring combination treatment. Abciximab reduced the occurrence of platelet-rich emboli in the filters from 42% to 7% (P<0.01). CONCLUSIONS - Renal artery stenting alone, stenting with embolic protection, and stenting with abciximab were associated with a decline in glomerular filtration rate. An unanticipated interaction between Angioguard and abciximab was seen, with combination therapy better than no treatment or either treatment alone.

KW - Kidney

KW - Peripheral vascular disease

KW - Platelets

KW - Stenosis

KW - Stents

UR - http://www.scopus.com/inward/record.url?scp=44449158362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449158362&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.107.730259

DO - 10.1161/CIRCULATIONAHA.107.730259

M3 - Article

VL - 117

SP - 2752

EP - 2760

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 21

ER -